Neurizon Therapeutics Limited has released a press release.
Shareholder Update - Progress and Strategy
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Demonstration batch of smaller size MPL tablets completed
- MND & COVID-19 Phase 1 Clinical Trials On-Track
- Canine phase 2b cancer trial expands to New Zealand
- MPL Manufacturing and Human Trials Update
- Following Extension of Survival, PAA Prepares Phase 3 Trial
Later from Neurizon Therapeutics
- Epichem Awarded Contract Extension from DNDi
- Update on Manufacture of MPL & Tablets for Clinical Trials
- Epichem Confirms Effectiveness of OHD E-Waste Project
- Appendix 4D & Half Year Report
- Key Appointment to Progress MPL COVID-19 Clinical Trial
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics